Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Account Payables (2020 - 2025)

RxSight (RXST) has disclosed Change in Account Payables for 6 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 1800.0% year-over-year to $2.2 million, compared with a TTM value of $627000.0 through Dec 2025, down 33.72%, and an annual FY2025 reading of $627000.0, down 33.72% over the prior year.
  • Change in Account Payables was $2.2 million for Q4 2025 at RxSight, up from -$86000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.2 million in Q1 2025 and bottomed at -$3.7 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $200650.0, with a median of $138500.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables crashed 1779.21% in 2022, then soared 1800.0% in 2025.
  • Year by year, Change in Account Payables stood at $101000.0 in 2021, then plummeted by 1779.21% to -$1.7 million in 2022, then soared by 90.68% to -$158000.0 in 2023, then skyrocketed by 173.42% to $116000.0 in 2024, then skyrocketed by 1800.0% to $2.2 million in 2025.
  • Business Quant data shows Change in Account Payables for RXST at $2.2 million in Q4 2025, -$86000.0 in Q3 2025, and -$3.7 million in Q2 2025.